NCT06957054 (EXP-CTH120) is a clinical trial of Any in Fragile X Syndrome (FXS), sponsored by Connecta Therapeutics, S.L..

Who is sponsoring NCT06957054?

NCT06957054 is sponsored by Connecta Therapeutics, S.L..

What drugs are being tested in NCT06957054?

Interventions in NCT06957054: Any.

What condition does NCT06957054 study?

NCT06957054 studies Fragile X Syndrome (FXS), Neurotypical Adults.

Is NCT06957054 still recruiting?

NCT06957054 is currently completed. Last updated 4 May 2025.

Last reviewed 2025-05-04 · How we verify

NCT06957054: EXP-CTH120

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neural Biomarkers in Fragile X Syndrome

Completed Last updated 4 May 2025

What this trial tests

trial testing Any in Fragile X Syndrome (FXS) in 20 participants. Completed in 20 March 2025.

Timeline

16 December 2024

Primary endpoint
20 March 2025

20 March 2025

Quick facts

Lead sponsor	Connecta Therapeutics, S.L.
Status	Completed
Study type	OBSERVATIONAL
Enrollment	20
Start date	16 December 2024
Primary completion	20 March 2025
Estimated completion	20 March 2025
Sites	2 locations across Spain

Drugs / interventions tested

Any — full drug profile →

Conditions studied

Fragile X Syndrome (FXS) — all drugs for Fragile X Syndrome (FXS) →
Neurotypical Adults — all drugs for Neurotypical Adults →

Sponsor

Connecta Therapeutics, S.L. — full company profile →

Who can join

Adults 18 to 55, any sex, with Fragile X Syndrome (FXS) or Neurotypical Adults. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this non-interventional test /re-test study is to assess neural biomarkers in adult subjects with Fragile X syndrome compared to those measured in a population of typically developing adults

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Fragile X Syndrome (FXS)

Currently open trials in the same condition.

NCT07493096 — Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal Disor · recruiting
NCT06677866 — Group CBT in Adolescents With Fragile X Syndrome and in Adolescents With Autism Spectrum Disorder · NA · recruiting

Other Connecta Therapeutics, S.L. trials

Trials by the same sponsor.

NCT06480968 — CTH120 First-in-Human Study: Single and Multiple Ascending Doses and Potential Food Interaction · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06957054 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Connecta Therapeutics, S.L.
Last refreshed: 4 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06957054.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing